Japanese pharma Eisai is launching a first-of-its kind “digital business” that aims to help predict dementia while also helping those living with the debilitating disease live better lives. Eisai, ...
In August, Eisai Inc. cut the ribbon on a 15-story, 332,800-square-foot space that serves as the hub for the company, which is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd. “We try ...
Eisai has put direct-to-consumer (DTC) advertising at the heart of its ongoing efforts to expand demand for Leqembi. Seeking to grow prescriptions in the U.S., the Japanese drugmaker is now targeting ...
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK) and Biogen Inc. (BIIB) said that the U.S. Food and Drug Administration has accepted Eisai's Supplemental Biologics License Application or sBLA for ...
Eisai Co ((ESALF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Eisai Co.’s breakthrough Alzheimer’s drug Leqembi was cleared for use in the European Union, after the medicine was approved in the US and Japan. The European Commission approved the drug to treat ...
A woman allegedly threatened with an axe. Another reportedly attacked in her apartment. A man stabbed in the chest. Since residents began moving into the building in early June, Asteri has endured a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback